In AIH-MASLD patients, steroid-sparing regimens such as mycophenolate mofetil may be preferable to minimize the risk of worsening insulin resistance and hepatic lipid accumulation. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.